Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Schroll, T. Lange, M. Arzt, D. Sebah, B. Stoelcker, M. Pfeifer (Regensburg, Donaustauf, Germany). Improvement of exercise capacity due to beta blocker treatment in the model of MCT induced pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 1065

Member's Comments

No comment yet.

Related content which might interest you: Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Experimental hypoxia-induced pulmonary hypertension is prevented by moderate exercise training in mice Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Voluntary exercise increases survival and exercise capacity in a monocrotaline-induced pulmonary hypertension in rats Source: International Congress 2018 – Cardiopulmonary exercise testing in COPD and cardiovascular diseases Year: 2018 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary hypertension reduces exercise tolerance in COPD Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Impact of 3-months COVID-19 lockdown on exercise capacity in stable pulmonary arterial hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Exercise training in pulmonary hypertension improves muscle efficiency and exercise capacity Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Effects of exercise training in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 669 Year: 2009